Actinogen Medical Ltd (ASX:ACW) has received a $9 million R&D (research and development) tax incentive rebate for the 2024 fiscal year, based on clinical tests of its lead compound Xanamem – a prospective therapy for Alzheimer’s Disease and Depression. The R& D rebate – which for Actinogen amounted to $9,034,351 – is a Federal government program which provides companies with cash refunds for eligible research and development expenditure. Together with funds on hand, the rebate means Actinogen is financially supported up to mid-2026, facilitating its full enrolment of 220 participants in its Al…